MoonLake Immunotherapeutics - Class A Ordinary Shares MLTX 深 沪
已收盘 09-18 16:00:00 美东时间
53.11
+2.120
+4.16%
华盛通- 最 高55.05
- 今 开51.49
- 成交量 69.36万股
- 最 低 51.27
- 昨 收 50.99
- 总市值 28.41亿
- 52周最高 64.98
- 市盈率 静 --
- 换手率 1.30%
- 52周最低 35.11
- 委 比 95.35%
- 总股本 5348.68万
- 历史最高 64.98
- 量 比 1.96
- 振 幅 7.41%
- 历史最低 4.25
- 每 手 1
- 风险率 6.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MoonLake Immunotherapeutics Capital Markets Day Preview
The latest update is out from MoonLake Immunotherapeutics ( ($MLTX) ). MoonLake...
09-11 19:57
Cantor Fitzgerald Reiterates Overweight on MoonLake
Cantor Fitzgerald analyst Prakhar Agrawal reiterates MoonLake (NASDAQ:MLTX) with a Overweight.
09-10 01:18
MoonLake Immunotherapeutics downgraded on concerns about lack of near-term catalysts
Biopharma company MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded to Peer Perform from Outperform at Wolfe Research, citing concerns on overpromised timelines. MLTX down about 2% premarket. “...
08-26 21:06
Wolfe Research Downgrades MoonLake to Peer Perform
Wolfe Research analyst Andy Chen downgrades MoonLake (NASDAQ:MLTX) from Outperform to Peer Perform.
08-26 18:31
Oppenheimer’s top 32 ideas for August-September
Oppenheimer analysts updated their top equity ideas for the current month, adding (FRPT), (SLNO), and removing (WMT), and (EW), among others. These stocks are “the most timely” according to Oppenheime...
08-21 02:41
Oppenheimer’s top SMID ideas within high-growth themes
Oppenheimer research analysts outlined the top small-cap and mid-cap stocks that have exposure to several high-growth themes. These stocks are high-conviction “SMID-cap” ideas for 2024 with a market c...
07-11 00:46
Buy Rating Affirmed: MoonLake Immunotherapeutics’s Sonelokimab Poised for Multiple Indication Success
Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on MoonLake ...
06-11 18:18
MoonLake Immunotherapeutics Advances in Psoriatic Arthritis Trial
MoonLake Immunotherapeutics (MLTX) has provided an update. MoonLake Immunothera...
06-11 05:54
Needham Reiterates Buy on MoonLake, Maintains $66 Price Target
Needham analyst Serge Belanger reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $66 price target.
06-11 01:49
Needham Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)
Needham analyst Serge Belanger maintained a Buy rating on MoonLake Immunotherap...
06-11 01:45
